INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is projected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $8.31 on Thursday. The firm has a 50-day simple moving average of $8.14 and a two-hundred day simple moving average of $6.29. The company has a market cap of $220.97 million, a P/E ratio of -3.81 and a beta of 1.93. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $12.72.

Analysts Set New Price Targets

INMB has been the subject of a number of research reports. Maxim Group boosted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Scotiabank boosted their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.